Abstract
Background: Pyrazole derivatives have been reported as both anticancer and antiinflammatory agents.
Objective: This study was conducted to develop new pyrazole derivatives as potential anticancer and/or antiinflammatory agents. Their molecular mechanisms of action have been investigated.
Method: a series of new triarylpyrazole derivatives were synthesized. Their in vitro anticancer activity was tested against NCI-58 cancer cell line panel of nine cancer types. The most active compound 1a was tested against sixteen kinases, many of them are known to be over-expressed in leukemia and breast cancer. The most sensitive kinases were V600E-B-RAF, C-RAF, FLT3, and P38α/MAPK14. Compound 1a was further tested for caspase-3/7 activity and LDH release assay as measures of its apoptotic and necrotic activities against RPMI-8226. Moreover, the ability of compounds 1a, 1b, and 1g to inhibit nitric oxide and prostaglandin E2production in LPS-induced RAW 264.7 macrophages was also examined.
Results: Compounds 1a, 1c, and 1g showed the highest activities against the cancer cell line panel, with more inhibitory effects against leukemia and breast cancer subpanels. The highest activity was exerted by compound 1a. Its IC50 values against RPMI-8226, K-562 leukemia cell lines, and MDA-MB-468 breast cancer cell line were 1.71 μM, 3.42 μM, and 6.70 μM, respectively. The IC50 of compound 1a against P38α/MAPK14 kinase was 0.515 μM. The caspase activity was increased by 72% and 170% at 1.23 μM and 3.70 μM concentrations of compound 1a, respectively. Furthermore, compound 1b inhibited 80.26% and 95.31% of NO and PGE2 productions, respectively, at 50 μM concentration in the LPS-induced RAW 264.7 macrophages.
Conclusion: Compound 1a could kill the cells through induction of apoptosis rather than necrosis. Compound 1a was more selective against cancer cells than non-cancerous cells. In addition, the hydroxyl analogue 1b was the most active as antiinflammatory agent.
Keywords: Antiinflammatory, antiproliferative, nitric oxide, P38α/MAPK14 kinase, PGE2, 1, 3, 4-triarylpyrazole.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives
Volume: 17 Issue: 1
Author(s): Mohammed I. El-Gamal, Mohammed S. Abdel-Maksoud, Mahmoud M. Gamal El-Din, Ji-Sun Shin, Kyung-Tae Lee, Kyung Ho Yoo and Chang-Hyun Oh
Affiliation:
Keywords: Antiinflammatory, antiproliferative, nitric oxide, P38α/MAPK14 kinase, PGE2, 1, 3, 4-triarylpyrazole.
Abstract: Background: Pyrazole derivatives have been reported as both anticancer and antiinflammatory agents.
Objective: This study was conducted to develop new pyrazole derivatives as potential anticancer and/or antiinflammatory agents. Their molecular mechanisms of action have been investigated.
Method: a series of new triarylpyrazole derivatives were synthesized. Their in vitro anticancer activity was tested against NCI-58 cancer cell line panel of nine cancer types. The most active compound 1a was tested against sixteen kinases, many of them are known to be over-expressed in leukemia and breast cancer. The most sensitive kinases were V600E-B-RAF, C-RAF, FLT3, and P38α/MAPK14. Compound 1a was further tested for caspase-3/7 activity and LDH release assay as measures of its apoptotic and necrotic activities against RPMI-8226. Moreover, the ability of compounds 1a, 1b, and 1g to inhibit nitric oxide and prostaglandin E2production in LPS-induced RAW 264.7 macrophages was also examined.
Results: Compounds 1a, 1c, and 1g showed the highest activities against the cancer cell line panel, with more inhibitory effects against leukemia and breast cancer subpanels. The highest activity was exerted by compound 1a. Its IC50 values against RPMI-8226, K-562 leukemia cell lines, and MDA-MB-468 breast cancer cell line were 1.71 μM, 3.42 μM, and 6.70 μM, respectively. The IC50 of compound 1a against P38α/MAPK14 kinase was 0.515 μM. The caspase activity was increased by 72% and 170% at 1.23 μM and 3.70 μM concentrations of compound 1a, respectively. Furthermore, compound 1b inhibited 80.26% and 95.31% of NO and PGE2 productions, respectively, at 50 μM concentration in the LPS-induced RAW 264.7 macrophages.
Conclusion: Compound 1a could kill the cells through induction of apoptosis rather than necrosis. Compound 1a was more selective against cancer cells than non-cancerous cells. In addition, the hydroxyl analogue 1b was the most active as antiinflammatory agent.
Export Options
About this article
Cite this article as:
El-Gamal I. Mohammed, Abdel-Maksoud S. Mohammed, Gamal El-Din M. Mahmoud, Shin Ji-Sun, Lee Kyung-Tae, Yoo Ho Kyung and Oh Chang-Hyun, Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1871520616666160620074534
DOI https://dx.doi.org/10.2174/1871520616666160620074534 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Walking the Oxidative Stress Tightrope: A Perspective from the Naked Mole-Rat, the Longest-Living Rodent
Current Pharmaceutical Design Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Nano-SnCl4/SiO2 as a Catalyst for One-Pot Synthesis of Substituted 1H-Pyrazoles as Antifungal and Cytotoxic Agents
Letters in Organic Chemistry Non-Steroidal Progesterone Receptor Specific Ligands
Mini-Reviews in Medicinal Chemistry Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Medicinal Chemistry Development of Structure Activity Correlation Model on Azetidin-2-ones as Tubulin Polymerization Inhibitors
Letters in Drug Design & Discovery Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Novel Pharmacologic Approaches to the Prevention and Treatment of Ulcerative Colitis
Current Pharmaceutical Design Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Docking and In Silico ADMET Study Reveals Flavonoids as a Potential Inhibitor of Aromatase
Letters in Drug Design & Discovery Molecular Genetics and Epidemiology of Osteoporosis
Current Pharmacogenomics Life and Death Partners in Post-PCI Restenosis: Apoptosis, Autophagy, and The Cross-talk Between Them
Current Drug Targets Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling
Current Cancer Drug Targets Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Recent Developments on Thiourea Based Anticancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry